drugset / Trial / NCT05679570
Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)
Phase 2
Completed
20 enrolled
International University of Health and Welfare
Chugai Pharmaceutical · collabJapan Agency for Medical Research and Development · collabKeio University · collab
NaSingle-groupOpen-labelTreatment
Summary
Examine the efficacy of satralizumab in patients with pulmonary arterial hypertension (PAH) with immune-responsive phenotype serum interleukin-6 (IL-6) ≥ 2.73 pg/mL who have an inadequate response to existing drugs.
Timeline
- Start
- 2022-07-12
- Primary completion
- 2026-04-14
- Completion
- 2026-04-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Satralizumab | Monoclonal antibody | 120 mg | Subcutaneous |